Haist, M.; Stege, H.; Pemler, S.; Heinz, J.; Fleischer, M.I.; Graf, C.; Ruf, W.; Loquai, C.; Grabbe, S.
Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors—A Retrospective, Real-World Cohort Study. Cancers 2021, 13, 5103.
https://doi.org/10.3390/cancers13205103
AMA Style
Haist M, Stege H, Pemler S, Heinz J, Fleischer MI, Graf C, Ruf W, Loquai C, Grabbe S.
Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors—A Retrospective, Real-World Cohort Study. Cancers. 2021; 13(20):5103.
https://doi.org/10.3390/cancers13205103
Chicago/Turabian Style
Haist, Maximilian, Henner Stege, Saskia Pemler, Jaqueline Heinz, Maria Isabel Fleischer, Claudine Graf, Wolfram Ruf, Carmen Loquai, and Stephan Grabbe.
2021. "Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors—A Retrospective, Real-World Cohort Study" Cancers 13, no. 20: 5103.
https://doi.org/10.3390/cancers13205103
APA Style
Haist, M., Stege, H., Pemler, S., Heinz, J., Fleischer, M. I., Graf, C., Ruf, W., Loquai, C., & Grabbe, S.
(2021). Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors—A Retrospective, Real-World Cohort Study. Cancers, 13(20), 5103.
https://doi.org/10.3390/cancers13205103
